Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3A11-MMAE
- Development stage
- Preclinical
- Lead developer
- Manhattan Biosolutions
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
3A11-MMAE is an antibody-drug conjugate (ADC) consisting of the high-affinity murine monoclonal antibody 3A11, which targets fibroblast growth factor receptor 4 (FGFR4), conjugated to the cytotoxic payload monomethyl auristatin E (MMAE) via a cathepsin-cleavable valine-citrulline-p-aminobenzyloxycarbonyl (vc-PABC) linker. FGFR4 is a cell-surface receptor tyrosine kinase highly expressed in rhabdomyosarcoma (RMS) and other cancers, such as breast cancer and hepatocellular carcinoma, but minimally expressed in normal tissues. Upon binding to FGFR4, 3A11-MMAE is rapidly internalized and trafficked to lysosomes, where the linker is cleaved to release MMAE, which inhibits tubulin polymerization, leading to cell cycle arrest and apoptosis. 3A11-MMAE is being developed for the treatment of FGFR4-expressing malignancies, including rhabdomyosarcoma and breast cancer.
- Other names
- 3A11-monomethyl auristatin E
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on 3A11-MMAE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3A11-MMAE.